Health Disparities and SARS-COV-2 Evolution: A Focused Viral Genomics Study

健康差异和 SARS-COV-2 进化：一项重点病毒基因组学研究

• 批准号: 10381371
• 负责人: JOHN P. KIRWAN
• 金额: $ 73.76万
• 依托单位: LSU PENNINGTON BIOMEDICAL RESEARCH CTR
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-15 至 2022-08-04
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10381371
• 关键词: 2019-nCoV; Address; Adherence; Amino Acids; Antibodies; Antiviral Agents; Area; Awareness; Bioinformatics; Biological; Body mass index; CLIA certified; COVID-19; COVID-19 pandemic; COVID-19 patient; COVID-19 surveillance; COVID-19 vaccine; Cerebrovascular Disorders; Chronic; Chronic Disease; Chronic Kidney Failure; Classification Scheme; Clinical; Clinical Data; Communities; Community Health Education; Community Outreach; Data; Data Analytics; Diabetes Mellitus; Diffusion; Drops; Evolution; Gender; Genetic; Genetic Variation; Healthcare Systems; Human; Hypertension; Immune system; Immunity; Immunosuppressive Agents; Impairment; Individual; Infection; Information Dissemination; Institution; Knowledge; Laboratories; Length of Stay; Lifting; Linguistics; Louisiana; Malignant Neoplasms; Methods; Minority; Molecular Epidemiology; Monoclonal Antibodies; Mutation; Obesity; Outcome; Participant; Pathogenicity; Patients; Pattern; Phylogenetic Analysis; Population; Population Sizes; Preventive measure; Probability; Process; Renal dialysis; Reporting; Resource Informatics; SARS-CoV-2 genome; SARS-CoV-2 variant; Severities; Symptoms; Testing; Time; Transplant Recipients; Underinsured; Underserved Population; Uninsured; Vaccinated; Vaccination; Vaccines; Variant; Viral; Viral Drug Resistance; Viral Genome; Virus; Vulnerable Populations; age group; base; biomedical informatics; clinical phenotype; community engagement; comorbidity; design; epidemiologic data; health disparity; immune clearance; immunogenic; immunogenicity; improved; innovation; models and simulation; next generation sequencing; outreach; pandemic disease; pressure; programs; racial and ethnic; sequencing platform; study population; trend; variants of concern; viral genomics; virus genetics

Health Disparities and SARS-CoV-2 Evolution: A Focused Viral Genomics Study Project Summary/Abstract We hypothesize that prolonged COVID19 illness, re-infection, and/or post-vaccine infection in patients with chronic conditions are associated with specific SARS-CoV-2 lineages or mutations, and that increasing the awareness of the potential danger posed by variants of concern will improve testing adherence and variant tracking. We propose to use our established FDA- authorized COVID19 sequencing platform in combination with innovative data analytics and clinical bioinformatics as well as our BMI and community engagement KCAs. Our proposal addresses four of the priority areas indicated by NOT-GM-21-031, specifically: • Are there different variants present in the study population, and how has the number of cases caused by different variants changed over time in the study population? • How are different variants distributed among different racial, ethnical, gender, and/or age groups? • Are specific variants associated with different levels of manifestation of COVID19 symptoms? • Do vaccinated study participants still acquire the SARS-CoV-2 virus, and if so, what variants do they carry? We propose these Specific Aims: Specific Aim 1. To improve surveillance of COVID19 by integrating SARS-CoV-2 sequencing and clinical data with a focus on under-represented, vulnerable and remote populations. Using highly automated processes, we will identify variants/mutations associated with clinical phenotypes, including prolonged asymptomatic/antibody-positive individuals, re-infected, and vaccinated populations. All trend data will be integrated in the AWS cloud where it can be accessed by relevant stakeholders including testing and vaccine program partners. Specific Aim 2. To develop and validate simulation models that incorporate SARS-CoV-2 genetic data with clinical outcomes to predict COVID19 case severity in Louisiana by region as vaccination levels increase. Specific Aim 3. To design and deploy culturally and linguistically appropriate outreach material on SARS-CoV-2 and determine whether increased knowledge of the potential danger of adaptive mutations improves acceptance of testing and vaccination.

健康差异与SARS-CoV-2进化：一项针对性病毒基因组学研究 项目总结/摘要 我们假设，长期COVID 19疾病，再感染，和/或疫苗后感染， 患有慢性疾病的患者与特定的SARS-CoV-2谱系或突变有关， 提高对令人关切的变异体所构成的潜在危险的认识， 改进测试依从性和变体跟踪。我们建议使用我们现有的食品药品管理局- 授权的COVID 19测序平台结合创新的数据分析， 临床生物信息学以及我们的BMI和社区参与KCA。我们的建议 解决了NOT-GM-21-031中指出的四个优先领域，具体为： ·研究人群中是否存在不同的变异，病例数量如何 是由研究人群中随时间变化的不同变体引起的吗？ ·不同的变体如何在不同的种族、民族、性别和/或年龄中分布 群组？ ·特定变异是否与COVID 19症状的不同表现水平相关？ ·接种疫苗的研究参与者是否仍会感染SARS-CoV-2病毒，如果是，是什么变种 他们携带？ 我们提出这些具体目标： 具体目标1。通过整合SARS-CoV-2测序和 临床数据，重点关注代表性不足、弱势和偏远人群。使用高度 自动化过程，我们将识别与临床表型相关的变异/突变， 包括长期无症状/抗体阳性个体、再次感染和接种疫苗 人口。所有趋势数据都将集成到AWS云中， 包括检测和疫苗计划合作伙伴在内的相关利益攸关方。 具体目标2。开发并验证包含SARS-CoV-2基因的模拟模型 根据临床结局数据预测路易斯安那州各地区COVID 19病例的严重程度， 疫苗接种水平提高。 具体目标3。设计和部署在文化和语言上适当的宣传材料， SARS-CoV-2，并确定是否增加了对适应性疾病潜在危险的认识 基因突变提高了检测和疫苗接种的可接受性。